Welcome to our Evotec Blog.

Hope you will find our articles and resources relevant for your projects and interests.

Our experts are available for any additional information and to assist with your project challenges!

Just contact us.

 

 

2017

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene
Laura Catalina, 10 October 2017

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion of a screening campaign using Evotec’s induced...

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto
Nerina Coppini, 14 September 2017

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation
Nerina Coppini, 30 July 2017

We are pleased to share the press release published today about the agreement between Evotec AG and Aptuit under which Evotec will acquire Aptuit.

Read our article on Form Selection Problems in the Pharmaceutical Field
Nerina Coppini, 14 July 2017

Our Material Sciences and API experts Matteo Daldosso, Zadeo Cimarosti and Brigida Allieri have recently published an article where they discuss about the "form selection problem in the pharmaceutical field" and the importance of X-Rays Powder Diffraction technique to respond to the implications and challenges related to the API polymorphism. ...

Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics
Nerina Coppini, 8 June 2017

Provides range of discovery, CMC and non-clinical services Greenwich, CT, June 8, 2017 - Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc (Nasdaq:RGLS), an innovative biopharmaceutical company. The agreement includes a...

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter
Nerina Coppini, 23 May 2017

Our recent collaboration with Massachusetts General Hospital (MGH) on the identification and validation of novel targets in Gram-negative bacteria is covered in the Spring edition of OneNucleus Newsletter. Read the full article on page 8 with our expert, Antonio Felici.

Aptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development Operations
Nerina Coppini, 6 April 2017

Greenwich, CT, April 6, 2017 – Jonathan Goldman, CEO of Aptuit LLC, announced today that Henning Steinhagen, PhD, has been named as President, Research and Development Operations. Henning will continue in his existing role of Site-Head at Aptuit, Verona, Italy whilst assuming oversight of Aptuit global operations.His additional responsibilities...

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens
Nerina Coppini, 7 March 2017

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address antibiotic resistance in the treatment of serious...

 

 

Contact us

Evotec

Business Development

T +44.(0)1235.86 15 61 T +1.732 329 2355 x3308